90 related articles for article (PubMed ID: 25243268)
1. Intralesional bevacizumab as in-add adjuvant to immunocryosurgery for locally advanced basal cell carcinoma.
Gaitanis G; Bassukas I
J Eur Acad Dermatol Venereol; 2014 Aug; 28(8):1117-21. PubMed ID: 25243268
[TBL] [Abstract][Full Text] [Related]
2. Cryosurgery during Imiquimod (Immunocryosurgery) for Periocular Basal Cell Carcinomas: An Efficacious Minimally Invasive Treatment Alternative.
Gaitanis G; Kalogeropoulos CD; Bassukas ID
Dermatology; 2016; 232(1):17-21. PubMed ID: 26583773
[TBL] [Abstract][Full Text] [Related]
3. Immunocryosurgery for basal cell carcinoma: results of a pilot, prospective, open-label study of cryosurgery during continued imiquimod application.
Gaitanis G; Nomikos K; Vava E; Alexopoulos EC; Bassukas ID
J Eur Acad Dermatol Venereol; 2009 Dec; 23(12):1427-31. PubMed ID: 19555364
[TBL] [Abstract][Full Text] [Related]
4. Office-based treatment of basal cell carcinoma with immunocryosurgery: feasibility and efficacy.
Nakuçi M; Bassukas ID
Acta Dermatovenerol Alp Pannonica Adriat; 2013; 22(2):35-8. PubMed ID: 23836356
[TBL] [Abstract][Full Text] [Related]
5. Immunocryosurgery for non-superficial basal cell carcinoma: a pro-spective, open-label phase III study for tumours ≤ 2 cm in diameter.
Gaitanis G; Bassukas ID
Acta Derm Venereol; 2014 Jan; 94(1):38-44. PubMed ID: 23722308
[TBL] [Abstract][Full Text] [Related]
6. Immunocryosurgery for non-superficial basal cell carcinomas ≤ 20 mm in maximal diameter: Five-year follow-up.
Gaitanis G; Bassukas ID
J Geriatr Oncol; 2019 May; 10(3):475-478. PubMed ID: 30219274
[TBL] [Abstract][Full Text] [Related]
7. The Feasibility of Immunocryosurgery in the Treatment of Non-Superficial, Facial Basal Cell Carcinoma That Relapsed after Standard Surgical Excision: An Experience Report from Two Centers.
Gaitanis G; Zampeta A; Tsintzou P; Fillis G; Seretis K; Feldmeyer L; Bassukas I
Curr Oncol; 2022 Nov; 29(11):8475-8482. PubMed ID: 36354728
[TBL] [Abstract][Full Text] [Related]
8. Immunocryosurgery is a safe and feasible treatment for basal cell carcinoma and Bowen disease in renal transplant recipients.
Tsironi T; Gaitanis G; Pappas C; Koutlas V; Dounousi E; Bassukas ID
Dermatol Ther; 2022 May; 35(5):e15405. PubMed ID: 35194902
[TBL] [Abstract][Full Text] [Related]
9. Cryosurgery is more effective in the treatment of primary, non-superficial basal cell carcinomas when applied during and not prior to a five week imiquimod course: a randomized, prospective, open-label study.
Gaitanis G; Alexopoulos EC; Bassukas ID
Eur J Dermatol; 2011; 21(6):952-8. PubMed ID: 21926038
[TBL] [Abstract][Full Text] [Related]
10. Alterations in the inflammatory cells infiltrating basal cell carcinomas during immunocryosurgery.
Nomikos K; Lampri E; Spyridonos P; Bassukas ID
Arch Dermatol Res; 2019 Aug; 311(6):499-504. PubMed ID: 31115658
[TBL] [Abstract][Full Text] [Related]
11. [Basal cell carcinoma].
Takenouchi T
Gan To Kagaku Ryoho; 2006 Oct; 33(10):1398-403. PubMed ID: 17033227
[TBL] [Abstract][Full Text] [Related]
12. New treatment modalities for basal cell carcinoma.
Stockfleth E; Sterry W
Recent Results Cancer Res; 2002; 160():259-68. PubMed ID: 12079222
[TBL] [Abstract][Full Text] [Related]
13. Immunocryosurgery for patients with therapeutically challenging basal cell carcinomas: report of two representative cases.
Gaitanis G; Nomikos K; Vlachos C; Bassukas ID
J Dermatolog Treat; 2012 Feb; 23(1):70-1. PubMed ID: 20964570
[No Abstract] [Full Text] [Related]
14. Imiquimod can be combined with cryosurgery (immunocryosurgery) for locally advanced periocular basal cell carcinomas.
Gaitanis G; Kalogeropoulos C; Bassukas ID
Br J Ophthalmol; 2011 Jun; 95(6):890-2. PubMed ID: 21378006
[No Abstract] [Full Text] [Related]
15. Multidisciplinary management of advanced basal cell carcinoma: report of four cases.
Yu J; Aldabagh B; Wang J; Yom SS; El-Sayed I; Knott D; McGrath MH; Arron S;
J Drugs Dermatol; 2014 May; 13(5):601-6. PubMed ID: 24809887
[TBL] [Abstract][Full Text] [Related]
16. Application of a burn scar assessment tool for the evaluation of visual scarring following immunocryosurgery for facial basal cell carcinoma.
Gaitanis G; Spyridonos P; Seretis K; Moschovos V; Bassukas ID
Eur J Dermatol; 2022 Nov; 32(6):709-715. PubMed ID: 36856377
[TBL] [Abstract][Full Text] [Related]
17. High-dose bevacizumab in the treatment of patients with advanced clear cell renal carcinoma: a phase II trial of the Sarah Cannon Oncology Research Consortium.
Hainsworth JD; Shipley DL; Reeves J; Arrowsmith ER; Barnes EK; Waterhouse DM
Clin Genitourin Cancer; 2013 Sep; 11(3):283-289.e1. PubMed ID: 23684421
[TBL] [Abstract][Full Text] [Related]
18. Basal cell carcinoma.
Gupta AK; Daigle D; Martin G
Skinmed; 2014; 12(1):33-8; quiz 38. PubMed ID: 24720082
[TBL] [Abstract][Full Text] [Related]
19. Immunocryosurgery for basal cell carcinoma: impact on circulating CD4
Gaitanis G; Ganiatsa A; Vartholomatos G; Karamoutsios A; Pappas P; Bassukas ID
Eur J Dermatol; 2020 Oct; 30(5):605-606. PubMed ID: 32959782
[No Abstract] [Full Text] [Related]
20. A Review of Immunocryosurgery and a Practical Guide to Its Applications.
Gaitanis G; Bassukas ID
Diseases; 2021 Oct; 9(4):. PubMed ID: 34698134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
